WallStSmart

American Shared Hospital Service (AMS)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 226265% more annual revenue ($65.77B vs $29.05M). MRK leads profitability with a 13.6% profit margin vs -5.3%. MRK earns a higher WallStSmart Score of 50/100 (D+).

AMS

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.0Quality: 4.0
Piotroski: 4/9Altman Z: 0.97

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMSUndervalued (+28.0%)

Margin of Safety

+28.0%

Fair Value

$3.18

Current Price

$1.33

$1.85 discount

UndervaluedFair: $3.18Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMS2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

AMS4 concerns · Avg: 2.3/10
Market CapQuality
$9.08M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

EPS GrowthGrowth
-38.1%2/10

Earnings declined 38.1%

Altman Z-ScoreHealth
0.972/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AMS

The strongest argument for AMS centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AMS

The primary concerns for AMS are Market Cap, Return on Equity, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

AMS profiles as a growth stock while MRK is a value play — different risk/reward profiles.

AMS carries more volatility with a beta of 0.32 — expect wider price swings.

AMS is growing revenue faster at 15.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 36/100). AMS offers better value entry with a 28.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Shared Hospital Service

HEALTHCARE · MEDICAL CARE FACILITIES · USA

American Shared Hospital Services rents radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?